NASDAQ:PTLAPortola Pharmaceuticals Stock Price, Forecast & News

Portola Pharmaceuticals' stock was trading at $8.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTLA shares have increased by 109.7% and is now trading at $17.91. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Portola Pharmaceuticals.

Portola Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Portola Pharmaceuticals.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analysts' expectations of $33.88 million. Portola Pharmaceuticals had a negative return on equity of 267.86% and a negative net margin of 232.73%. The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.02) earnings per share. View Portola Pharmaceuticals' earnings history.

8 Wall Street analysts have issued 12 month target prices for Portola Pharmaceuticals' shares. Their forecasts range from $17.00 to $44.00. On average, they expect Portola Pharmaceuticals' share price to reach $29.14 in the next year. This suggests a possible upside of 62.7% from the stock's current price. View analysts' price targets for Portola Pharmaceuticals.

News coverage about PTLA stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a news impact score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutPortola Pharmaceuticals.

Some companies that are related to Portola Pharmaceuticals include United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), PPD (SDGR), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Exelixis (EXEL), Amarin (AMRN), Geron (GERN), NVIDIA (NVDA), Inovio Pharmaceuticals (INO) and Aileron Therapeutics (ALRN).

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

Portola Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (13.67%), William Blair Investment Management LLC (12.74%), BlackRock Inc. (7.76%), State Street Corp (4.13%), Rock Springs Capital Management LP (2.23%) and Fiera Capital Corp (2.17%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Hollings Renton, Jeffrey W Bird, Mardi Dier and William Lis. View institutional ownership trends for Portola Pharmaceuticals.

PTLA stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Pictet Asset Management Ltd., BlackRock Inc., Rafferty Asset Management LLC, Tekla Capital Management LLC, Fiera Capital Corp, Blair William & Co. IL, and Pinnacle Associates Ltd.. View insider buying and selling activity for Portola Pharmaceuticals.

PTLA stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Rock Springs Capital Management LP, Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Two Sigma Advisers LP, Two Sigma Investments LP, and Wellington Management Group LLP. View insider buying and selling activity for Portola Pharmaceuticals.

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTLA stock can currently be purchased for approximately $17.91.

Portola Pharmaceuticals has a market capitalization of $1.41 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290,660,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.

The official website for Portola Pharmaceuticals is www.portola.com.

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]